AVITA Medical to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference
AVITA Medical Inc (NASDAQ:RCEL) A Bull Case Theory
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $15
TD Cowen analyst Josh Jennings maintains $Avita Medical(RCEL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 54.4% and a
Why Avita Medical, Car Group, Dicker Data, and JB Hi-Fi Shares Are Soaring Today
Avita Medical Target Price Cut 19% to A$4.56/Share by Morgans>AVH.AU
Avita Medical Upgraded to Buy From Hold by Bell Potter
AVITA Medical Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Avita Medical Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results.
Cantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $21 Price Target
AVITA Medical Analyst Ratings
Lake Street Issues a Buy Rating on Avita Medical (RCEL)
BTIG Remains a Hold on Avita Medical (RCEL)
Is AVITA Medical, Inc. (RCEL) Among the Best Cosmetic Surgery and Aesthetics Stocks to Buy Now?
Express News | AVITA Medical Inc : TD Cowen Cuts Target Price to $15 From $25
Avita Medical Maintains Buy Rating Amid Strong Quarterly Performance and Positive Growth Outlook
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Expects To Achieve Previously Given Guidance Of Cashflow Break Even And GAAP Profitability No Later Than The End Of Q3 Of 2025
Express News | AVITA Medical Inc - Commercial Revenue for Q3 2024 Is Expected to Be in Range of $19.0 to $20.0 Mln
AVITA Medical Q2 2024 GAAP EPS $(0.60) Misses $(0.48) Estimate, Sales $15.195M Beat $14.733M Estimate
10-Q: Q2 2024 Earnings Report